Literature DB >> 19616557

X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution.

Tsuyoshi Watabe1, Yukihiro Terakawa, Kentaro Watanabe, Hiroaki Ohno, Hiroaki Nakano, Toru Nakatsu, Hiroaki Kato, Kazuki Izumi, Eiichi Kodama, Masao Matsuoka, Kazuo Kitaura, Shinya Oishi, Nobutaka Fujii.   

Abstract

The S138A substitution of fusion inhibitory peptides derived from the C-terminal heptad repeat (C-HR) of the human immunodeficiency virus type 1 (HIV-1) gp41 leads to enhanced binding affinity to the N-terminal heptad repeat (N-HR). As such, these peptides exhibit highly potent anti-HIV-1 activity. X-ray crystallographic analysis was performed to understand the effect of the substitution on binding affinity. The comparison of the native and S138A crystal structures indicated that the increase in the hydrophobicity of the S138A substitution may aid the stabilization of the N-HR/C-HR complex through additional hydrophobic contacts. Free-energy calculations suggest that the difference between the desolvation free energies of the C-HR-derived peptides with and without the S138A mutation dominates the observed difference in anti-HIV-1 activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616557     DOI: 10.1016/j.jmb.2009.07.027

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  11 in total

1.  Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.

Authors:  Dirk Eggink; Ilja Bontjer; Johannes P M Langedijk; Ben Berkhout; Rogier W Sanders
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.

Authors:  Kazuki Shimane; Kumi Kawaji; Fusako Miyamoto; Shinya Oishi; Kentaro Watanabe; Yasuko Sakagami; Nobutaka Fujii; Kazuya Shimura; Masao Matsuoka; Mitsuo Kaku; Stefan G Sarafianos; Eiichi N Kodama
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

3.  Potent anti-HIV-1 activity of N-HR-derived peptides including a deep pocket-forming region without antagonistic effects on T-20.

Authors:  Kazuki Izumi; Kentaro Watanabe; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Stefan G Sarafianos; Eiichi N Kodama
Journal:  Antivir Chem Chemother       Date:  2011-08-23

4.  Origins of resistance to the HIVgp41 viral entry inhibitor T20.

Authors:  Brian E McGillick; Trent E Balius; Sudipto Mukherjee; Robert C Rizzo
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

5.  Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.

Authors:  Kazuya Shimura; Daisuke Nameki; Keiko Kajiwara; Kentaro Watanabe; Yasuko Sakagami; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Stefan G Sarafianos; Eiichi N Kodama
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

6.  Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.

Authors:  Kazuki Izumi; Kumi Kawaji; Fusasko Miyamoto; Kazuki Shimane; Kazuya Shimura; Yasuko Sakagami; Toshio Hattori; Kentaro Watanabe; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Mitsuo Kaku; Stefan G Sarafianos; Eiichi N Kodama
Journal:  Int J Biochem Cell Biol       Date:  2013-01-26       Impact factor: 5.085

7.  HIV-1 envelope accessible surface and polarity: clade, blood, and brain.

Authors:  Gopichandran Sowmya; Gunasagaran Shamini; Sathyanarayanan Anita; Meena Sakharkar; Venkat Mathura; Hector Rodriguez; Andrew J Levine; Elyse Singer; Deborah Commins; Charurut Somboonwit; John T Sinnott; Harcharan S Sidhu; Ganapathy Rajaseger; Peter Natesan Pushparaj; Pandajarasamme Kangueane; Paul Shapshak
Journal:  Bioinformation       Date:  2011-03-22

Review 8.  Current perspectives on HIV-1 antiretroviral drug resistance.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Viruses       Date:  2014-10-24       Impact factor: 5.048

Review 9.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

10.  Computer-Aided Approaches for Targeting HIVgp41.

Authors:  William J Allen; Robert C Rizzo
Journal:  Biology (Basel)       Date:  2012-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.